

Supplementary Material

Supplementary materials to this manuscript include patient's HF etiology (Table S1) at study baseline, a complete list of medication used under the scope of the program (Table S2), and a correlation analysis between relative differences in EF values and other variables of interest (Figure S1).

Table S1. Patients' HF etiology at baseline.

Etiology	<i>n</i>	%
Non-Ischemic Dilated Cardiomyopathy	19	35.2%
Ischemic Cardiomyopathy	12	22.2%
Cardiotoxicity (alcohol)	6	11.1%
Dilated Cardiomyopathy in study	3	5.6%
Myocarditis	3	5.6%
Cardiotoxicity (anthracyclines)	2	3.7%
Valvular Disease	2	3.7%
Tachycardiomyopathy	2	3.7%
Non-compacted Cardiomyopathy	1	1.9%
Peri-partum Cardiomyopathy	1	1.9%
Hypertensive heart disease	1	1.9%
Infiltrative heart disease (amyloidosis)	1	1.9%
Neuromuscular disease	1	1.9%

Table S2. Distribution of the prescribed medication and implanted devices among patients.

Medication	<i>n</i>	% (out of 54)
<u>No medication</u>	1	1.9
<u>1 Drug</u>	2	3.7
BB (<i>no target</i>)	1	1.9
MRA (<i>target</i>)	1	1.9
<u>2 Drugs</u>	12	22.2
BB + ARB	5	9.3
Target	4	7.4
No target	1	1.9
BB + ACEi/ARB (<i>target</i>)	3	5.6
BB + MRA	2	3.7
Target	1	1.9
No target	1	1.9
ACEi/ARB + MRA (<i>no target</i>)	1	1.9
ARNI + MRA (<i>no target</i>)	1	1.9
<u>3 Drugs</u>	39	72.2
BB + ARNI + MRA	15	27.8
BB (<i>target</i>) + ARNI (<i>target</i>) + MRA (<i>target</i>)	1	1.9
BB (<i>target</i>) + ARNI + MRA	1	1.9
BB + ARNI (<i>target</i>) + MRA	4	7.4
BB + ARNI (<i>target</i>) + MRA (<i>target</i>)	1	1.9
BB + ARNI + MRA (<i>all no target</i>)	7	13.0
BB + ARNI + MRA (<i>target</i>)	1	1.9
BB + ACEi/ARB + MRA	24	44.4
BB (<i>target</i>) + ACEi/ARB (<i>target</i>) + MRA	1	1.9
BB (<i>target</i>) + ACEi/ARB + MRA (<i>target</i>)	1	1.9
BB + ACEi/ARB (<i>target</i>) + MRA	4	7.4
BB + ACEi/ARB + MRA (<i>all no target</i>)	16	29.6

BB + ACEi/ARB + MRA (<i>target</i>)	2	3.7
Implanted devices	n	% (out of 54)
None	33	61.1%
ICD (1 st prevention)	7	13.0%
ICD (2 nd prevention)	3	5.6%
CRT-P	4	7.4%
CRT-D (1 st prevention)	7	13%

ACEi = angiotensin-converting enzyme inhibitors; ARB = angiotensin receptor blockers; ARNI = angiotensin receptor - neprilysin inhibitors; BB = beta blockers; MRA = mineralcorticoid-receptor antagonists; CRT-D = implantable cardiac resynchronization therapy defibrillator; CRT-P = cardiac resynchronization therapy pacemaker; ICD = implantable cardioverter-defibrillator.

Table S3. Follow-up time characteristics of the patients that had EF data at follow-up (n=39).

Follow-up	Months
Average	7.9
Standard deviation	3.3
Median (IQR)	8 (5;11)
Minimum	3
Maximum	15




Figure S1. Scatterplots of the correlation analysis between relative differences in EF and other continuous variables: **A)** **B)** follow-up time, **C)** NT-proBNP values at baseline, **D)** NT-proBNP values at follow-up and **E)** relative differences in NT-proBNP values. Analyses were performed using Pearson's coefficient, and Spearman's correlation coefficient was used to assess the relationships.